|

Datopotamab Deruxtecan Clinical Trials

10 actively recruiting trials across 6 locations

▼ -1 trial since June 2026

Also known as: DS-1062, DS-1062; DS-1062a, Dato-DXd, DS-1062a, Dato-DXd, Dato-DXd, DS-1062a +2 more

Pipeline

Phase 2: 6Phase 3: 2Phase 1/2: 1

Top Sponsors

  • AstraZeneca3
  • UNC Lineberger Comprehensive Cancer Center1
  • Sarah Sammons, MD1
  • QuantumLeap Healthcare Collaborative1
  • Medical University of Vienna1

Indications

Other3 trials

A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
Phase 2
Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
Phase 2

Birmingham, Alabama2 trials

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

University of Alabama at Birmingham

Phase 2
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

University of Alabama

Phase 2

Anchorage, Alaska1 trial

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site

Phase 3

Fountain Valley, California1 trial

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Research Site

Phase 3

San Francisco, California1 trial

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

Research Site

Phase 1/2

Miami, Florida1 trial

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Miami Baptist Cancer Institute/

Phase 2

Chapel Hill, North Carolina1 trial

PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

UNC Lineberger Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.